Device Trial Radar · NCT03421626
Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)
Last checked: Nov 20, 2026Latest source record: Apr 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
266
Actual
Start
Nov 8, 2017
Primary completion
Aug 20, 2018
Study completion Aug 20, 2018
Sponsor
- Lead sponsor
- CepheidNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 5, 2018
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.
Conditions
- Leukemia, Myelogenous, Chronic
Interventions
Xpert BCR-ABL UltraDevice
Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML
Primary outcomes
What the sponsor says the trial is designed to measure.
- Method comparison to an on-market molecular diagnostic assayTime frame: Baseline = testing upon enrollment
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Broward Oncology Associates
Fort Lauderdale, Florida
St. Alphonsus Regional Medical Center
Boise, Idaho
WJB Dorn VA Medical Center
Columbia, South Carolina
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.